Bioscience Americas is raising $15 million through an investment offering to build three stem cell treatment centers in South America. Stem cell therapy uses a patient's own cells and has helped millions suffering from degenerative diseases. Investors will receive ownership units projected to provide a 31% average annual return over five years and a potential 10 times return on investment. The company is partnered with respected research institutions to advance regenerative treatments using stem cells.

1. BROADMARKETING, LLC
Randy Broadus, Principal
502-709-0495 | broadmarketing1@yahoo.com | www.bioscienceamericas.com
This information contains “forward-looking statements” that may or may not materialize. This information does not constitute an offer to buy or sell any security nor is it a solicitation to buy or sell any security. Such
offers can only be made by the Company’s Private Placement Memorandum which is available upon request.
Projected Annual Cash Returns After
Stabilization
Year One 4%
Year Two 16%
Year Three 48%
Year Four 87%
Investment Proposal
n $10,000 Minimum Investment (One Unit)
n 31% Average Annual Return Over Five Years
n Capital Gain From IPO or Sale
n Nearly 10X Total ROI in 5 years
n IRA Qualified
Investment Summary
Bioscience Americas is raising $15,000,000 through a Regulation
D 506(c) Private Placement to qualified Accredited Investors to
construct and operate three stem cell treatment centers in South
America. Investors receive ownership units and will receive a
pro-rata share of the Company’s profits. The average annual cash
distribution for the first five years is projected to be 31%.
We also project that investors will benefit from an appreciation in
equity value by as much as 10X after five years.
History & Overview
n Helping millions suffering from degenerative diseases.
n Regenerative treatment using stem cell therapy is the future of medicine.
n Therapies utilize the patient’s own stem cells for treatment.
n Partnered with the Global Institute of Stem Cell Therapy and Research.
n Associated with several world-class hospitals.
n Affiliated with major research universities throughout the world.
n Raising $15 million to fund three stem cell therapy clinics.
31% Average Annual Return
87% Distribution in Year 5
10X ROI in 5 Years

2. Background & Overview.
Regenerative medicine using stem cell therapy is proving to
be the future of medical treatment for many degenerative
diseases and injuries. Currently under FDA approved clinical
trials, these treatments have been proven successful in
Europe and other international markets for tens of thousands
of patients. Bioscience Americas was formed to partner
with the Global Institute of Stem Cell Therapy and Research
(GIOSTAR) to develop three autologous stem cell treatment
centers. Located at the University of California Medical
Center in San Diego, GIOSTAR is recognized as one of the
world’s leading stem cell research groups and has been the
beneficiary of more than $400 million in research funding.
What are Stem Cells and how do they
repair the body?
Stem Cells have the remarkable ability to develop into any cell
type in the body. They serve as the body’s primary internal
repair system, dividing essentially without limit to repair and
replenish other cells. If there’s an injury, chronic disease, or
inflammation a stem cell has the ability to differentiate into
whatever cell type is needed to fix the problem such as a
muscle cell, bone cell, or a nerve cell, etc. When healthy stem
cells are injected into the injured or diseased area, they work
primarily by turning on and augmenting the body’s own repair
mechanism.
The science and the team behind it.
The Bioscience Americas/GIOSTAR research team is headed
by Dr. Anand Srivastava considered by many to be the “Father
of Stem Cell Research”. Our team is a consortium of leading
stem cell scientists and we maintain affiliations with many
universities throughout the world. Our team opened the
world’s first dedicated stem cell therapy hospital in India in
2011. Since then we have successfully treated more than
4,000 patients using only adult stem cells for regeneration and
rejuvenation treatments. These stem cells are derived from
the patient’s own body fat or bone marrow and then injected
back into the problem areas of the body using a procedure
called induced pluripotent. This science has been used to
successfully treat diseases including diabetes, multiple
sclerosis, lupus, and other autoimmune diseases as well
as various orthopedic injuries and many other degenerative
diseases.
The Market.
Considering the vast array of diseases and injuries that could
benefit from stem cell treatment we estimate that there are
over 60 million potential patients in the U.S. alone. Chronic
diseases account for $3 out of every $4 spent on healthcare.
This easily equates to a market of over $1 trillion each year
for our treatments. In 2013 over 1.2 million Americans sought
medical treatment outside of the U.S. and this number is
expected to grow about 20% annually. We are planning to
open our next facility at the world renowned San Vicente
Hospital.
Business Model.
Bioscience Americas shares with GIOSTAR the treatment
revenuesandancillaryincomefromthethreeproposedclinics.
The cost of treatments range from $15,000 to approximately
$40,000. We anticipate treating about three patients a day in
year one growing to twenty patients a day in year five.
Marketing Plan.
Our plan is to use a multifaceted approach to recruit patients
including: medical tourism, referrals, patient education
through disease support groups, public presentations,
internet, and physician seminars. We also expect to receive
many direct referrals from our hospital affiliations.
BROADMARKETING, LLC
Randy Broadus, Principal
502-709-0495 | broadmarketing1@yahoo.com | www.bioscienceamericas.com
This information contains “forward-looking statements” that may or may not materialize. This information does not constitute an offer to buy or sell any security nor is it a solicitation to buy or sell any security. Such
offers can only be made by the Company’s Private Placement Memorandum which is available upon request.